

Remarks

Claims 1-18 have been cancelled without prejudice or disclaimer of the subject matter therein. Applicants retain the right to pursue the subject matter of claims 1-18 in continuing applications. Claims 19-66 have been added (and are directed to the invention of Group III). Support for claims 19-66 can be found throughout the specification and the original claims. Specifically, support can be found, *inter alia*, at page 8, lines 8-11, page 79, line 10, to page 84, line 15, and page 85, line 24, to page 111, line 24. These amendments add no new matter and their entry is respectfully requested.

After entry of the above amendment, claims 19-66 are pending in the application, with claims 19, 29, 39, and 48 being the independent claims.

Conclusion

It is respectfully believed that this application is now in condition for substantive examination. Early notice to this effect is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Karen R. Markowicz
Agent for Applicants
Registration No. 36,351

Date: August 3, 2001

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600

Version with markings to show changes made

In the Title:

Page 1, line 1: Antibodies to Human Tumor Necrosis Factor Receptor-Like Genes

In the Abstract:

Page 204, line 1: Antibodies to Human Tumor Necrosis Factor Receptor-Like Genes

In the Claims:

Claims 1-18 have been cancelled.

Claims 19-66 have been newly added.